A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

Follow us in Kenya!

Read time:
PATH/Wendy Stone

This is an exciting week for the GHTC. Not only are we launching our “Breakthroughs” blog, but we’re also taking off on an amazing trip to Kenya to discover how global health research is changing people’s lives on the ground.

October 9, 2011 by Kaitlin Christenson

Mother and Child in Kenya

This is an exciting week for the GHTC. Not only are we launching our “Breakthroughs” blog, but we’re also taking off on an amazing trip to Kenya to discover how global health research is changing people’s lives on the ground. We can’t wait to share live updates on our blog from the trip, and give you a sense for the incredible progress taking place in Kenya. We’re very fortunate to be meeting with several GHTC members conducting ground-breaking work in Kenya. In Nairobi, we have plans to meet with local researchers from the Drugs for Neglected Diseases initiative (DNDi), the International AIDS Vaccine Initiative (IAVI), and the International Partnership for Microbicides (IPM). DNDi is leading an incredible effort to create new treatments for visceral leishmaniasis, or VL, a painful and deadly disease that affects half a million people worldwide each year. IPM and IAVI are leading work to develop new HIV prevention methods in the form a vaccine (IAVI), as well as gels, rings and other products women can use to protect themselves against HIV (IPM).

Also while we’re in Nairobi, the GHTC is meeting with several dedicated American officials working on global health research in Kenya. These committed US citizens work with agencies such as the State Department, the US Embassy, and the Centers for Disease Control and Prevention (CDC). They’ll share with us why the US Government thinks research for new global health tools is so critical to American interests at home and abroad.

After Nairobi, we’ll visit Kisumu in Western Kenya. Kisumu is home to some of the most exciting health research going on in Kenya, including an incredible partnership several US agencies have with the Kenya Medical Research Institute (KEMRI). The CDC has been working with KEMRI for 30 years, and we’ll be visiting some exciting research projects the CDC/KEMRI partnership is working on with GHTC members. For example, there’s some remarkable vaccine research going on in and around Kisumu—GHTC member Aeras is conducting research for a new tuberculosis (TB) vaccine among infants in the region. And we’ll get the chance to hear about a ground-breaking study, called HPTN 052, on using antiretroviral drugs for HIV prevention in couples. The Department of Defense (DoD) also has a long history of medical research in Kisumu that we’ll get the hear more about during our visit.

Finally, we’ll be visiting a great program in western Kenya run by our secretariat PATH. The program, called APHIA II, provides comprehensive health care and prevention services for diseases such as HIV and AIDS, TB, and links these services to others that improve maternal and child health. APHIA shows the impact of lifesaving tools - such as drugs, vaccines, bed nets, and other treatments – that only exist as a result of the research investments that helped to develop them.

We hope you’re as excited about the GHTC’s trip as we are. We’re thrilled to share these stories with you, and hope you follow us throughout the week.

About the author

Kaitlin ChristensonGHTC

Kaitlin Christenson is director of GHTC.

Other Breakthroughs Blog posts you may like:
USAID/Alex Kamweru
November 11, 2024

Research Roundup: First-of-its-kind mpox vaccine trial, New treatment-resistant malaria drug, Genetically modified mosquitos

Written by Hannah Sachs-Wetstone / GHTC
Read time:
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. A new, first-of-its-kind trial will assess the safety and immunogenicity of Bavarian Nordic’s MVA-BN mpox vaccine in pregnant and breastfeeding women and infants under two years old, two populations at risk of severe complications from mpox but not currently eligible for vaccination. MVA-BN is the only vaccine for mpox prequalified by the World Health Organization and is currently approved for healthy adults and adolescents, but additional data from this trial could help expand access for additional key populations amid the ongoing mpox outbreak. The trial, which will start early next year, is jointly funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Global Health EDCTP3.Researchers from the University of Glasgow have developed a new drug that could help combat the spread of treatment-resistant malaria, as the disease continues to kill more than 600,000 people every year and Plasmodium falciparum, a mosquito vector that spreads malaria, grows increasingly resistant to artemisinin, the frontline malaria treatment. The drug, adapted from a cancer treatment approach, works by permanently disabling a protein that P. falciparum uses to duplicate itself in humans. The researchers behind the drug think it could be more effective than current drugs at all stages of malaria infection, potentially with only one dose.A research team from the University of California, Santa Barbara has found a way to potentially reduce the spread of mosquito-borne diseases by disrupting male mosquitoes’ ability to hear, which is essential for them to mate and breed. Male mosquitoes rely on the sound of female mosquitoes’ wingbeats in order to find and mate with them. By altering a genetic pathway that male mosquitoes use for hearing, the researchers were able to stop them mating entirely, preventing female mosquitoes, the ones that spread diseases to humans, from having babies and reducing overall mosquito populations. Specifically, the researchers studied Aedes aegypti mosquitoes, which spread diseases including dengue, yellow fever, and Zika.
PATH/Enoch Kavindele Jr.
November 4, 2024

Research Roundup: Noninvasive malaria test, Mpox vaccine trial for kids, Novel class of antimicrobial agents

Written by Hannah Sachs-Wetstone / GHTC
Read time:
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. Recently published research found that a new, noninvasive test for malaria could provide a more reliable, safer, quicker, and more sensitive diagnostic option in low- and middle-income countries. The Cytophone, a tabletop printer-sized device, uses targeted lasers and ultrasound to detect malaria-infected cells in the bloodstream via a small, noninvasive probe placed on the back of a person’s hand. Malaria-infected red blood cells accumulate a by-product with unique properties that can be distinguished from normal red blood cells when they pass through a laser. The test, which provides results within minutes, was found to be as good or better at detecting symptomatic Plasmodium falciparum malaria infections than the current gold standard point-of-care methods for malaria testing, which require blood samples and special laboratory equipment. The next phase of testing the device will also investigate whether the device can detect and distinguish between other species.Last Tuesday, Bavarian Nordic announced the start of a clinical study of the MVA-BN® mpox/smallpox vaccine in children between 2 and 11 years old, who are highly vulnerable to infection during the ongoing mpox emergency. The study, which currently has sites in the Democratic Republic of Congo and plans to include sites in Uganda as well, is investigating the safety and immunogenicity of the vaccine in children compared to adults. Last month, the World Health Organization prequalified the vaccine for adolescents between 12 and 17 years old, following the European Medicines Agency’s approval for this age group. Results from the new trial could support an extension of the current approval.Researchers have identified a novel class of antimicrobial agents known as encrypted peptides that play a key role in the immune system’s response to bacterial infections, opening up new possibilities for combating drug-resistant infections as antimicrobial resistance continues to grow as a global health threat. The immune system is traditionally thought to rely primarily on proteins explicitly linked to immune functions, but this new research reveals that other structural proteins contribute to antimicrobial defenses. Leveraging the immune system’s natural defenses through these non-immune proteins could allow researchers to develop effective antibiotic therapies less prone to resistance.